Hong Kong GLP-1 buyer's guide 2026: HK private clinics + the Bangkok-hop story

Hong Kong is the SE Asia market we cover that has been most underserved by our existing buyers guides. The HK private medical infrastructure is excellent and the regulatory posture is reasonable, but pricing runs at the high end of the regional band and the cost-arbitrage with Bangkok is sharp. This is the first dedicated read.

What HK Department of Health licenses

The HK Department of Health Drug Office maintains the registration list for Hong Kong. As of May 2026:

• Wegovy (semaglutide 2.4mg) · registered for chronic weight management with BMI ≥ 30 or ≥ 27 with comorbidity
• Ozempic (semaglutide diabetes label) · registered for type-2 diabetes; off-label weight-management prescribing common at private clinics
• Mounjaro (tirzepatide diabetes label) · registered for type-2 diabetes; off-label weight-management common
• Saxenda (liraglutide) · registered for chronic weight management

Zepbound (tirzepatide weight-management label) is not registered in HK as of May 2026. Wegovy is the cleanest weight-management-indication route; off-label Mounjaro use through diabetes prescribing is the practical tirzepatide path.

Per-clinic pricing, May 2026

HK private clinics run premium across the board. Out-of-pocket is the norm; private health insurance (Bupa, AXA, Manulife, Cigna) coverage for weight-management GLP-1 varies by plan and is increasingly being excluded as a specific carve-out.

Clinic	Wegovy 2.4mg	Mounjaro 5mg	Mounjaro 10mg	Consult fee

| OT&P Healthcare | HKD 8,500 to 10,500 | HKD 6,200 to 8,000 | HKD 7,800 to 10,000 | HKD 800 to 1,500 | | Central Health Medical Practice | HKD 9,000 to 11,500 | HKD 6,500 to 8,500 | HKD 8,200 to 10,800 | HKD 900 to 1,800 | | Quality HealthCare | HKD 8,200 to 10,200 | HKD 6,000 to 7,800 | HKD 7,600 to 9,800 | HKD 700 to 1,400 | | Hong Kong Sanatorium & Hospital | HKD 9,500 to 12,500 | HKD 7,000 to 9,200 | HKD 8,800 to 11,500 | HKD 1,200 to 2,500 |

Converted to USD at the May 2026 rate: roughly USD 1,050 to 1,600 for Wegovy, USD 770 to 1,470 for Mounjaro depending on dose and clinic. This is the highest band in our SE Asia matrix.

The Bangkok-hop math from Hong Kong

HK-BKK is a 2h55 flight. Cathay, HK Express, AirAsia, Thai Airways all run multiple daily flights. Round-trip economy 30-day-advance booking lands USD 220 to 480 off-peak (HK is a higher-cost origin than SG, VN, or KL for the same hop).

The break-even calculation comparing HK private clinic Mounjaro 5mg to the Bangkok mid-tier with one round-trip flight per 8-week supply:

• HK private Mounjaro 5mg per month: ~USD 770 (no flight)
• Bangkok Mounjaro 5mg per month + flight amortized over 8-week supply: ~USD 220 + ~USD 175 flight share = ~USD 395

The Bangkok hop saves roughly USD 350 to 400 per month at the mid-tier even with the more expensive HK-BKK flight. At higher tirzepatide doses the absolute savings scale up. The Wegovy comparison is even sharper · HK Wegovy at USD 1,050+ per month vs Bangkok Wegovy at USD 320 to 560 + flight share.

The picture: Hong Kong has the steepest local-vs-Bangkok cost differential of any SE Asia origin we cover. The hop is the dominant cost-optimal path for any HK-resident expat without insurance coverage.

When the HK local clinic wins anyway

Three scenarios where the local relationship beats the hop:

1. Insurance carve-in. Some legacy HK private health plans (older Bupa Gold tier, certain Cigna Platinum plans) still cover Wegovy without a weight-management exclusion. If your plan is one of these, the out-of-pocket beats the Bangkok cost. 2. Comorbid clinical complexity. T2D, cardiovascular monitoring, kidney function tracking · the integrated specialist network at HK Sanatorium or OT&P is hard to replicate via cross-border resupply. 3. High billable-hour cost-of-time. The Bangkok hop is roughly one work-day of opportunity cost per 8 to 12 weeks. HK professional rates make this calculation flip for a meaningful slice of the cohort.

What we route to

The matchmaker quiz at /quiz routes HK-resident users similarly to Singapore: HK + premium-budget + complex-comorbidity → local clinic recommendation; HK + cost-conscious + simpler-clinical-picture → Bangkok-hop hybrid recommendation. The Bangkok-hop playbook covers the cross-border mechanics; the premium-hospital comparison covers the BKK end of the journey.

HK clinic scorecards on the 11-signal rubric are queued for the next vendor-catalog round. Until they ship, the HK private network is best understood through the existing clinic websites + the Department of Health drug register; we will not score blind.